Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with an overall 5-year survival rate of 6%. The molecular mechanisms that contribute to the biological aggressiveness of PDAC are being gradually elucidated, and the crucial role of high and low frequency driver mutations in PDAC is providing new insights into the complexity of this cancer. However, the widespread consequences of aberrant transforming growth factor-beta (TGF-beta) actions in PDAC in the context of the presence of oncogenic Kras and loss of function of the retinoblastoma protein are not well understood. In this proposal we will use a novel genetically engineered mouse model (GEM) of PDAC that we generated in which oncogenic Kras is combined with RB deletion. The resultant KRC mice rapidly develop pancreatic intraepithelial (PanIN) lesions that progress to PDAC within weeks after birth, and the pancreatic cancer cells in these cancers are highly proliferative. Based on our published data and preliminary results, the KRC mouse will allow us to test the hypothesis that aberrant TGF-beta signaling in PDAC synergizes with RB inactivation, leading to deleterious actions by TGF-beta, aberrant mitogenic signaling, and enhanced pancreatic cancer cell proliferation and cancer cell-stroma interactions. We will evaluate the effects of RB loss of function on TGF-beta signaling, assess the role of TGF-beta signaling in PDAC metastasis, and delineate the contributions of inflammatory cytokines and Wnt pathways to pancreatic cancer cell proliferation and stroma formation. To this end we will use cell lines established from KRC pancreata, use other novel GEMs of PDAC generated in our laboratory that exhibit a high incidence of metastases, conduct therapeutic interventions in these GEMs, and assess the role of these pathways in human PDAC. The proposed studies will advance our understanding of PDAC pathobiology in a high impact manner, and will point the way to novel therapies for suppressing cancer growth and metastasis.
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer that is notoriously resistant to treatment, and the proposed plan to study novel aspects of PDAC in relation to abnormal mitogenic actions by transforming growth factor beta (TGF-beta) in the context of oncogenic Kras and retinoblastoma protein (RB) loss of function will greatly enhance our knowledge of this cancer. The proposal is relevant to public health because it is designed to delineate novel mechanisms that promote pancreatic cancer cell growth and metastasis, to evaluate the relevance of these mechanisms in relation to developmental and inflammatory signals, and to uncover novel therapies for suppressing pancreatic cancer cell proliferation and metastasis, which could then be translated into reduced morbidity and mortality.
|Eibl, Guido; Cruz-Monserrate, Zobeida; Korc, Murray et al. (2018) Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. J Acad Nutr Diet 118:555-567|
|Simpson, Rachel E; Yip-Schneider, Michele T; Wu, Huangbing et al. (2018) Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm. Am J Surg :|
|Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912|
|Quirin, Kayla A; Kwon, Jason J; Alioufi, Arafat et al. (2018) Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. Mol Ther Methods Clin Dev 8:8-20|
|Liu, Hung-Yi; Korc, Murray; Lin, Chien-Chi (2018) Biomimetic and enzyme-responsive dynamic hydrogels for studying cell-matrix interactions in pancreatic ductal adenocarcinoma. Biomaterials 160:24-36|
|Kota, Janaiah; Hancock, Julie; Kwon, Jason et al. (2017) Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Lett 391:38-49|
|Lai, Xianyin; Wang, Mu; McElyea, Samantha Deitz et al. (2017) A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett 393:86-93|
|Duell, Eric J; Lujan-Barroso, Leila; Sala, Núria et al. (2017) Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. Int J Cancer 141:905-915|
|Prabhu, Lakshmi; Wei, Han; Chen, Lan et al. (2017) Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers. Oncotarget 8:39963-39977|
|Nguyen, Hai V; Gore, Jesse; Zhong, Xin et al. (2016) MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection. J Gastrointest Surg 20:1699-706|
Showing the most recent 10 out of 88 publications